Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Exp Hematol Oncol
Главные авторы: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2021
Предметы:
Letter to the Editor
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://ncbi.nlm.nih.gov/pubmed/33397455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00186-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы